» Articles » PMID: 34113478

Can Plasma α-Synuclein Help Us to Differentiate Parkinson's Disease from Essential Tremor?

Overview
Publisher Ubiquity Press
Date 2021 Jun 11
PMID 34113478
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Studies have revealed controversial results regarding the diagnostic accuracy of plasma α-synuclein levels in patients with Parkinson's disease (PD). This study was aimed to analyze the diagnostic accuracy of plasma α-synuclein in PD versus healthy controls and patients with essential tremor (ET).

Methods: In this cross-sectional study, we included de novo (n = 19) and advanced PD patients [OFF (n = 33), and On (n = 35) states], patients with ET (n = 19), and controls (n = 35). The total plasma α-synuclein levels were determined using an ELISA sandwich method. We performed adjusted multivariate regression analysis to estimate the association of α-synuclein levels with group conditions [controls, ET, and de novo, OFF and ON-PD]. We studied the diagnostic accuracy of plasma α-synuclein using the area under the curve (AUC).

Results: The plasma α-synuclein levels were higher in controls compared to PD and ET (p < 0.0001), discriminating de novo PD from controls (AUC = 0.74, 95% CI 0.60-0.89), with a trend towards in advanced PD (OFF state) from ET (AUC = 0.69, 95% CI 0.53-0.84).

Conclusions: This is the first study examining and comparing plasma α-synuclein levels in ET vs. PD and controls. Preliminary findings suggest that plasma α-synuclein levels might help to discriminate de novo and advanced PD from controls and ET.

Citing Articles

Exploring serum α‑synuclein and its autoantibodies in essential tremor: implications for diagnosis and symptom correlations.

Shalash A, Doma A, Barakat M, Hamid E, Salama M Biomed Rep. 2024; 21(1):108.

PMID: 38868525 PMC: 11168024. DOI: 10.3892/br.2024.1796.


Erythrocytic alpha-synuclein as potential biomarker for the differentiation between essential tremor and Parkinson's disease.

Yu Z, Liu G, Zheng Y, Huang G, Feng T Front Neurol. 2023; 14:1173074.

PMID: 37693770 PMC: 10483808. DOI: 10.3389/fneur.2023.1173074.


Correction: Can Plasma α-Synuclein Help Us to Differentiate Parkinson's Disease from Essential Tremor?.

Albillos S, Montero O, Calvo S, Solano B, Trejo J, Cubo E Tremor Other Hyperkinet Mov (N Y). 2021; 11:24.

PMID: 34221699 PMC: 8231448. DOI: 10.5334/tohm.637.

References
1.
Bougea A, Stefanis L, Paraskevas G, Emmanouilidou E, Vekrelis K, Kapaki E . Plasma alpha-synuclein levels in patients with Parkinson's disease: a systematic review and meta-analysis. Neurol Sci. 2019; 40(5):929-938. DOI: 10.1007/s10072-019-03738-1. View

2.
Mollenhauer B, Caspell-Garcia C, Coffey C, Taylor P, Shaw L, Trojanowski J . Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls. Neurology. 2017; 89(19):1959-1969. PMC: 5679418. DOI: 10.1212/WNL.0000000000004609. View

3.
Bolstad N, Warren D, Nustad K . Heterophilic antibody interference in immunometric assays. Best Pract Res Clin Endocrinol Metab. 2013; 27(5):647-61. DOI: 10.1016/j.beem.2013.05.011. View

4.
Espay A, Lang A, Erro R, Merola A, Fasano A, Berardelli A . Essential pitfalls in "essential" tremor. Mov Disord. 2017; 32(3):325-331. PMC: 5359065. DOI: 10.1002/mds.26919. View

5.
Bidinosti M, Shimshek D, Mollenhauer B, Marcellin D, Schweizer T, Lotz G . Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening. J Biol Chem. 2012; 287(40):33691-705. PMC: 3460466. DOI: 10.1074/jbc.M112.379792. View